MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Hypertrophic growth, a risk factor for mortality in heart disease, is driven by reprogramming of cardiac gene expression. Although the transcription factor myocyte enhancer factor-2 (MEF2) is a common end point for several hypertrophic pathways, its precise cardiac gene targets and function in cardiac remodeling remain to be elucidated.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Circulation

Title: Circulation

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1524-4539

ISSN (Print): 0009-7322

Publication date (Electronic): Jul 25 2006

Volume: 114

Issue: 4

Affiliations

[1 ] Hubrecht Laboratory, and Interuniversity Cardiology Institute Netherlands, Royal Netherlands Academy of Sciences, Utrecht, Netherlands.

Article

Publisher Item ID: CIRCULATIONAHA.105.608968

DOI: 10.1161/CIRCULATIONAHA.105.608968

PubMed ID: 16847152

SO-VID: 9f2eff5a-ec60-41ca-8351-f0331d85ae19

History

Data availability:

Comments

Comment on this article

scite_

0

Smart Citations

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.